POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
about
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice.Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.CXCR4-directed theranostics in oncology and inflammation
P2860
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@ast
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@en
type
label
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@ast
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@en
prefLabel
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@ast
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@en
P2093
P2860
P356
P1433
P1476
POL5551, a novel and potent CX ...... chemotherapy in pediatric ALL
@en
P2093
Barbara Romagnoli
Colleen E Annesley
Daniel Magoon
Edward Allan R Sison
Garry J Douglas
Gerald Tuffin
Johann Zimmermann
Patrick Brown
P2860
P304
30902-30918
P356
10.18632/ONCOTARGET.5094
P407
P577
2015-09-03T00:00:00Z